Prevent the Preventable

Patient safety is the utmost importance to you. We understand. It is for us too. Quantitative Neuromuscular Blockade Monitoring augments your clinical expertise and provides unwavering confidence in clinical decision making from start to finish.

Senzime´s innovative device, TetraGraph, supports the optimization of patient management in patients receiving neuromuscular blocking agents (NMBAs). TetraGraph can be used from start to finish during the surgical procedure. The monitor enables objective assessment of the depth of block and titration of medication dosage to help determine when the patient has recovered sufficiently to maintain spontaneous breathing.

Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The Senzime AB (publ) share are listed on NASDAQ Stockholm First North Growth Market. Short name: SEZI.

Residual Neuromuscular Blockade

Qualitative vs Quantitative Monitorin

EMG

The new Gold Standard

Press releases

Communique from extra general meeting in Senzime AB (publ)

Read more

Senzime expands US sales team and signs additional distribution agreements

Read more

Notice of extra general meeting in Senzime AB (Publ)

Read more
See all »

News

Senzime Joins the Anesthesia Patient Safety Foundation (APSF) as a member of the Corporate Advisory Counsel

Read more

The latest evidence in the Management of Neuromuscular Blockade

Read more

Senzime secures the first sales in the US market

Read more
See all »